Unprecedented advances have been made in cancer treatment with the use of immune
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and …

Resistance to anticancer therapies includes primary resistance, usually related to lack of
target dependency or presence of additional targets, and secondary resistance, mostly …

While CRISPR screens are helping uncover genes regulating many cell-intrinsic processes,
existing approaches are suboptimal for identifying extracellular gene functions, particularly …

Abstract N6-methyladenosine (m6A) modification can regulate a variety of biological
processes. However, the implications of m6A modification in lung adenocarcinoma (LUAD) …

Owing to a lack of response to the anti-PD1 therapy for most cancer patients, we develop a
network approach to infer genes, pathways, and potential therapeutic combinations that are …

Neutrophils are the most abundant of the circulating immune cells and are the first to be
recruited to sites of inflammation. Neutrophils are a heterogeneous group of immune cells …

Simple Summary Tumour heterogeneity is a phenomenon where the cancer cells evolve
diversely over the course of the disease. As a result of the evolution, the cancer cells can be …

Background Numerous studies have used multi-region sampling approaches to characterize
intra-tumor heterogeneity (ITH) in hepatocellular carcinoma (HCC). However, conventional …

Extramedullary disease (EMD) is a high-risk feature of multiple myeloma (MM) and remains
a poor prognostic factor, even in the era of novel immunotherapies. Here, we applied spatial …

Recent advances in treating cutaneous melanoma have resulted in impressive patient
survival gains. Refinement of disease staging and accurate patient risk classification have …